Chemotherapy of invasive thymoma

Adriano Fornasiero, Otello Daniele, Cristina Ghiotto, Francesco Sartori, Federico Rea, Mario Piazza, Luciano Fiore-Donati, Paolo Morandi, Savina M L Aversa, Adriano Paccagnella, Giovanni L. Pappagallo, Mario V. Fiorentino

Research output: Contribution to journalArticlepeer-review


Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988. All patients received the following chemotherapy in 4-day courses: 50 mg/m2 of cisplatin intravenously (IV) and 40 mg/m2 of doxorubicin IV on day 1;0.6 mg/m2 of vincristine IV on day 3; and 700 mg/m2 of cyclophosphamide IV on day 4 (ADOC). The courses were repeated every 3 weeks, and toxic effects were tolerable. The radiologically defined overall clinical response rate (complete plus partial response) was 91% with 47% clinical complete remissions; median time to progression was 11 months (range, 0 to 96) and the median estimated (Kaplan-Meier) progression-free interval was 22 months. Five of the 15 clinical complete remissions were pathologically confirmed at thoracotomy. We believe the ADOC regimen qualifies for adjuvant and preoperative treatment of invasive thymoma due to the high complete response and overall response rates.

Original languageEnglish
Pages (from-to)1419-1423
Number of pages5
JournalJournal of Clinical Oncology
Issue number8
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Chemotherapy of invasive thymoma'. Together they form a unique fingerprint.

Cite this